Pharmacologic and therapeutic strategies in treatment-resistant depression. Switching antidepressants vs. conventional augmentation strategies (Q83755816)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 March 2009

Language	Label	Description	Also known as
English	Pharmacologic and therapeutic strategies in treatment-resistant depression. Switching antidepressants vs. conventional augmentation strategies	scientific article published on 01 March 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19407715%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Pharmacologic and therapeutic strategies in treatment-resistant depression. Switching antidepressants vs. conventional augmentation strategies (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19407715%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

G I Papakostas

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19407715%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

1 March 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19407715%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

C N S Spectrums

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19407715%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19407715%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

3 Suppl 4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19407715%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

11-14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19407715%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Risperidone for treatment-refractory major depressive disorder: a randomized trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

EPS profiles: the atypical antipsychotics are not all the same

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel augmentation strategy for treating resistant major depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of second generation antipsychotics: a systematic review of randomized trials

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

Is there a role for 5-HT1A agonists in the treatment of depression?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

Empirical testing of two models for staging antidepressant treatment resistance.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900003527

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1017/S1092852900003527

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19407715%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19407715%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83755816&oldid=1608429043"